000272867 001__ 272867
000272867 005__ 20250127091435.0
000272867 0247_ $$2pmc$$apmc:PMC11514033
000272867 0247_ $$2doi$$a10.1038/s41598-024-76668-4
000272867 0247_ $$2pmid$$apmid:39462124
000272867 0247_ $$2altmetric$$aaltmetric:169925913
000272867 037__ $$aDZNE-2024-01284
000272867 041__ $$aEnglish
000272867 082__ $$a600
000272867 1001_ $$aYousefi, Elham$$b0
000272867 245__ $$aEfficiency of multivariate tests in trials in progressive supranuclear palsy.
000272867 260__ $$a[London]$$bMacmillan Publishers Limited, part of Springer Nature$$c2024
000272867 3367_ $$2DRIVER$$aarticle
000272867 3367_ $$2DataCite$$aOutput Types/Journal article
000272867 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730714744_2966
000272867 3367_ $$2BibTeX$$aARTICLE
000272867 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272867 3367_ $$00$$2EndNote$$aJournal Article
000272867 520__ $$aMeasuring disease progression in clinical trials for testing novel treatments for multifaceted diseases as progressive supranuclear palsy (PSP), remains challenging. In this study we assess a range of statistical approaches to compare outcomes as measured by the items of the progressive supranuclear palsy rating scale (PSPRS). We consider several statistical approaches, including sum scores, a modified PSPRS rating scale that had been recommended by FDA in a pre-IND meeting, multivariate tests, and analysis approaches based on multiple comparisons of the individual items. In addition, we propose two novel approaches which measure disease status based on Item Response Theory models. We assess the performance of these tests under various scenarios in an extensive simulation study and illustrate their use with a re-analysis of the ABBV-8E12 clinical trial. Furthermore, we discuss the impact of the FDA-recommended scoring of item scores on the power of the statistical tests. We find that classical approaches as the PSPRS sum score demonstrate moderate to high power when treatment effects are consistent across the individual items. The tests based on Item Response Theory (IRT) models yield the highest power when the simulated data are generated from an IRT model. The multiple testing based approaches have a higher power in settings where the treatment effect is limited to certain domains or items. The study demonstrates that there is no one-size-fits-all testing procedure for evaluating treatment effects using PSPRS items; the optimal method varies based on the specific effect size patterns. The efficiency of the PSPRS sum score, while generally robust and straightforward to apply, varies depending on the specific patterns of effect sizes encountered and more powerful alternatives are available in specific settings. These findings can have important implications for the design of future clinical trials in PSP and similar multifaceted diseases.
000272867 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000272867 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000272867 650_7 $$2Other$$aClinical trials
000272867 650_7 $$2Other$$aItem response theory
000272867 650_7 $$2Other$$aMultiple endpoints
000272867 650_7 $$2Other$$aMultivariate tests
000272867 650_7 $$2Other$$aProgressive supranuclear palsy
000272867 650_7 $$2Other$$aSimulation study
000272867 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: diagnosis
000272867 650_2 $$2MeSH$$aHumans
000272867 650_2 $$2MeSH$$aMultivariate Analysis
000272867 650_2 $$2MeSH$$aClinical Trials as Topic
000272867 650_2 $$2MeSH$$aDisease Progression
000272867 7001_ $$aGewily, Mohamed$$b1
000272867 7001_ $$aKönig, Franz$$b2
000272867 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b3$$udzne
000272867 7001_ $$0P:(DE-2719)9003372$$aHopfner, Franziska$$b4$$udzne
000272867 7001_ $$aKarlsson, Mats O$$b5
000272867 7001_ $$aRistl, Robin$$b6
000272867 7001_ $$aZehetmayer, Sonja$$b7
000272867 7001_ $$aPosch, Martin$$b8
000272867 773__ $$0PERI:(DE-600)2615211-3$$a10.1038/s41598-024-76668-4$$gVol. 14, no. 1, p. 25581$$n1$$p25581$$tScientific reports$$v14$$x2045-2322$$y2024
000272867 8564_ $$uhttps://pub.dzne.de/record/272867/files/DZNE-2024-01284%20SUP1.pdf
000272867 8564_ $$uhttps://pub.dzne.de/record/272867/files/DZNE-2024-01284%20SUP2.xlsx
000272867 8564_ $$uhttps://pub.dzne.de/record/272867/files/DZNE-2024-01284.pdf$$yOpenAccess
000272867 8564_ $$uhttps://pub.dzne.de/record/272867/files/DZNE-2024-01284%20SUP2.csv
000272867 8564_ $$uhttps://pub.dzne.de/record/272867/files/DZNE-2024-01284%20SUP2.ods
000272867 8564_ $$uhttps://pub.dzne.de/record/272867/files/DZNE-2024-01284%20SUP2.xls
000272867 8564_ $$uhttps://pub.dzne.de/record/272867/files/DZNE-2024-01284%20SUP1.pdf?subformat=pdfa$$xpdfa
000272867 8564_ $$uhttps://pub.dzne.de/record/272867/files/DZNE-2024-01284.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272867 909CO $$ooai:pub.dzne.de:272867$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000272867 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000272867 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9003372$$aExternal Institute$$b4$$kExtern
000272867 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000272867 9141_ $$y2024
000272867 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000272867 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)1040$$2StatID$$aDBCoverage$$bZoological Record$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSCI REP-UK : 2022$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-04-12T15:11:06Z
000272867 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-04-12T15:11:06Z
000272867 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272867 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-24
000272867 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-24
000272867 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000272867 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger$$lTranslational Neurodegeneration$$x1
000272867 980__ $$ajournal
000272867 980__ $$aVDB
000272867 980__ $$aUNRESTRICTED
000272867 980__ $$aI:(DE-2719)1111015
000272867 980__ $$aI:(DE-2719)1110002
000272867 9801_ $$aFullTexts